Volume 2, Issue 6, November 2014, Page: 106-111
Comparison between Micro-Dose GnRH Agonist and GnRH Antagonist Protocol in Poor Responders Undergoing Intracytoplasmic Sperm Injection with Embryo Transfer
Moez Kdous, Aziza Othmana Hospital, Department of Obstetrics and Gynecology, IVF Center, 1008, Tunis, Tunisia
Ghaya Merdassi, Aziza Othmana Hospital, Department of Obstetrics and Gynecology, IVF Center, 1008, Tunis, Tunisia
Fethi Zhioua, Aziza Othmana Hospital, Department of Obstetrics and Gynecology, IVF Center, 1008, Tunis, Tunisia
Received: Sep. 27, 2014;       Accepted: Oct. 23, 2014;       Published: Nov. 20, 2014
DOI: 10.11648/j.jgo.20140206.16      View  2877      Downloads  166
Abstract
Objective: To compare the effect of the multiple-dose GnRH antagonist protocol with the microdose GnRH agonist flare-up (MF) protocol in poor ovarian responders for ICSI. Design: Retrospective, Clinical study. Setting:IVF center. Patient(s): Two hundred eighty-six poor responder patients undergoing ICSI-embryo transfer cycle. Intervention(s): one hundred Forty four patients (144 cycles) included in group 1 (microdose GnRH-a flare-up protocol) and one hundred fourty two patients (42 cycles) included in group 2 (multiple dose GnRH antagonist protocol). Main Outcome Measure(s): Serum E2 levels, number of growing follicles and mature oocytes, embryo quality, dose of gonadotropin used, cancellation, fertilization, implantation rate, pregnancy rate (PR) and live birth rate (LR). Results: Total gonadotropin dose used was significantly lower (2730235,45 vs 3189317,81; P<0.05), duration of stimulation was significantly longer and E2 level was significantly higher in group 1. The mean number of oocytes retrived, mature oocytes retrived, embryos transferred and the rate of at least one top-quality embryo transferred was similar in the two groups. The implantation rate was significantly higher in the microdose flare-up group than in the multiple-dose antagonist group (18.79% vs 8.28%; P<.001). Clinical pregnancy and live birth rates were similar in the two groups. Conclusion(s): We achieved comparable pregnancy and live birth rates in poor responders with the use of either GnRH antagonist or flare protocol. However, a significantly higher gonadotropin dose used and lower implantation rate in the antagonist group tips the balance in favor of the flare-up protocol.
Keywords
Cetrorelix, GnRH Antagonist, IVF, Embryo, Micro-Dose GnRH Agonist Flare-Up, Poor Ovarian Response
To cite this article
Moez Kdous, Ghaya Merdassi, Fethi Zhioua, Comparison between Micro-Dose GnRH Agonist and GnRH Antagonist Protocol in Poor Responders Undergoing Intracytoplasmic Sperm Injection with Embryo Transfer, Journal of Gynecology and Obstetrics. Vol. 2, No. 6, 2014, pp. 106-111. doi: 10.11648/j.jgo.20140206.16
Reference
[1]
Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L; on behalf of the ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod 2011; 26:1616-1624.
[2]
Nikolaos P, Polyzos A, Paul D. A systematic review of randomized trials for the treatment of poor ovarian responders: is there any light at the end of the tunnel? Fertil Steril 2011;96:1058-1061.
[3]
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Fertil Steril 2004; 81:19-25.
[4]
Detti L, Williams DB, Robins JC, Maxwell RA, Thomas MA. A comparison of three downregulation approaches for poorresponders undergoing in vitro fertilization Fertil Steril 2005; 84: 1401–1405.
[5]
Schoolcraft W, Schlenker T, Gee M, Stevens J, Wagley L. Improved controlled ovarian hyperstimulation in poorresponder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol. Fertil Steril 1997; 67: 93–97.
[6]
Scott RT, Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization Fertil Steril 1994; 61: 880–885.
[7]
Surrey ES, Bower J, Hill, Ramsey J, Surrey MW. Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poorresponders who are undergoing in vitro fertilization Fertil Steril 1998; 69: 419–424.
[8]
Kyrou D, Kolibianakis EM, Venetis CA, Papanikolaou EG, Bontis J, Tarlatzis BC. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil Steril 2009; 91:749-66.
[9]
Alyaa E, Jessica SM, Lawrence E, John N, Claudio B. Luteal phase estradiol versus luteal phase estradiol and antagonist protocol for controlled ovarian stimulation before in vitro fertilization in poor responders. Fertil Steril 2011; 95: 324-326.
[10]
Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, M. Bahceci. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poorresponders: results of a prospective randomized trial. Hum Reprod 2001 ; 16 : 868–870.
[11]
S. Malmusi A. La Marca S. Giulini S. Xella D. Tagliasacchi, T. Marsella et al. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poorresponders undergoing ovarian stimulation. Fertil Steril 2005; 84: 402–406.
[12]
Schmidt DW, T. Bremner, J.J. Orris, D.B. Maier, C.A. Benadiva, J.C. Nulsen. A randomized prospective study of microdose leuprolide versus ganirelix in in vitro fertilization cycles for poorresponders Fertil Steril 2005; 83: 1568–1571.
[13]
G. De Placido, A. Mollo, R. Clarizia, I. Strina, S. Conforti, C. Alviggi. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response. Fertil Steril 2006; 85: 247–250.
[14]
S.J. Fasouliotis, N. Laufer, S. Sabbagh-Ehrlich, A. Lewin, A. Hurwitz, A. Simon. Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poorresponders undergoing IVF. J Assist Reprod Genet 2003; 20: 455–460.
[15]
Franco JR, Baruffi RLR, Mauri AL, Petersen CG, Felipe V, Cornicelli J, et al. GnRH agonist versus GnRH antagonist in poor ovarian responders: a meta-analysis. Reprod Biomed Online 2006;13:618–27.
[16]
Kahraman K, Berker B, Atabekoglu CS, Sonmezer M, Cetinkaya E, Aytac R, Satiroglu H. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle. Fertil Steril 2009;91:2437-44.
[17]
Lainas TG, Sfontouris IA, Papanikolaou EG, Zorzovilis JZ, Petsas GK, Lainas GT, Kolibianakis EM. Flexible GnRH antagonist versus flare-up GnRH agonist protocol in poor responders treated by IVF: a randomized controlled trial. Hum Reprod 2008;23:1355-8.
[18]
Zakia Mahdy Ibrahim, Heba Younes Mohamed Youssef, Magda Moustafa Elbialy, Mohamed Mouselhy Farrag. Micro-dose flare-up gonadotrophin-releasing hormone (GnRH) agonist vs. flexible gonadotrophin-releasing hormone (GnRH) antagonist protocol in patient with poor ovarian reserve. Middle East Fertility Society Journal 2011; 16: 272-277.
[19]
J. Garecia-Velasco, V. Isaza, C. Vidal, A. Landazabal, J. Remohi, C. Simon et al. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix). Hum Reprod 2001;16:2533–2539.
[20]
Malmusi S, La Marca A, Giulini S, Xella S, Tagliasacchi D, Marsella T, et al. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation. Fertil Steril 2005;84:402–6.
[21]
Demirol A, Gurgan T.Comparison of microdose flare-up and antagonist multiple-dose protocols for poor-responder patients: a randomized study. . Fertil Steril 2009;92:481-5.
[22]
Hakan yarali, İbrahim Esinler, Mehtap Polat, Gurkan Bozdag, Bulent Tiras. Antagonist/letrozole protocol in poor ovarian responders for intracytoplasmic sperm injection: a comparative study with the microdose flare-up protocol. Fertil Steril 2009;92:231-235.
[23]
E.M. Casañ, F. Raga, M.L. Polan. GnRH mRNA and protein expression in human preimplantation embryos. Mol. Hum Reprod 1999;5:234–239.
[24]
G. Emons, V. Muller, O. Ortmann, K.D. Schulz. Effects of LH-RH analogues on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol, 65 (1998), pp. 199–206
[25]
W.J. Murdoch. Immunolocalization of a GnRH receptor site in murine endometrium that mediates apoptosis. Cell Tissue Res 1995;282:527–529.
[26]
O. Ortmann, K. Diedrich. Pituitary and extrapituitary actions of gonadotrophin-releasing hormone and 1st analogues. Hum Reprod 1999;14:194–206.
[27]
Yannis Prapas, Stamatios Petousis, Themistoklis Dagklis, Yannis Panagiotidis, Achilleas Papatheodorou, Iuliano Assunta, Nikos Prapas. GnRH antagonist versus long GnRH agonist protocol in poor IVFresponders: a randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2012;25:208-209.
[28]
Robab Davar, Homa Oskouian, Shahnaz Ahmadi, Razieh Dehghani Firouzabad. GnRH Antagonist/Letrozole Versus Microdose GnRH Agonist Flare Protocol in Poor Responders Undergoing In Vitro Fertilization. Taiwanese J Obst Gynecol 2010;49:297-301
[29]
D. Minaretzis, M. Jakubowski, J.F. Mortola, S.N. Pavlou. Gonadotrophin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. J Clin Endocrinol Metab 1995;80:430–434.
[30]
E.R. Hernandez. Embryo implantation and GnRH antagonists. Hum Reprod 2000;15:1211–1216.
[31]
F. Olivennes, J.S. Cuhna-Filho, R. Fanchin, P. Bouchard, R. Frydman. The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update 2002;8:279–290.
[32]
B.C. Tarlatzis, L. Zepiridis, G. Grimbizis, J. Bontis. Clinical management of low ovarian response to stimulation for IVFa systematic review. Hum Reprod Update 2003;9:61–76.
[33]
Inna Berin, Daniel E. Stein, Martin D. Keltz. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization. Fertil Steril 2010;93:360-363.
[34]
S.J. Fasouliotis, N. Laufer, S. Sabbagh-Ehrlich, A. Lewin, A. Hurwitz, A. Simon. Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poorresponders undergoing IVF. J Assist Reprod Genet 2003;20:455–460.
Browse journals by subject